ArticleCentral-European journal of immunology2025
Macrophage M2 polarization induced by ANKRD22 in lung adenocarcinoma facilitates tumor angiogenesis.
Article in Central-European journal of immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- RNA-Seq Analysis of Human Cumulus Cells Identifies Angiogenic Pathways Associated with Infertility.Cells · 2026Article
- When protein stability drives tumor progression.Central-European journal of immunology · 2026Article
- WISP-3 promotes angiogenesis in non-small cell lung cancer through p38/JNK-c-Jun-mediated PDGF-A upregulation.Journal of Cancer · 2026Article
- Identification and validation of the potential therapeutic value of CASK in osteosarcoma: a computational analysis andFrontiers in oncology · 2026Article
- Shaping the macrophage landscape in the tumour microenvironment.Central-European journal of immunology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Lung adenocarcinoma (LUAD), the most prevalent lung cancer type, poses a great threat to public health, with its incidence and mortality rates remaining alarmingly high. While ankyrin repeat domain-containing protein 22 (ANKRD22) is linked to the development of multiple cancers, the molecular mechanisms of its impact on the malignant progression of LUAD are not yet fully understood. This study seeks to elucidate the biological role of ANKRD22 in LUAD. Material and methods: ANKRD22 expression in LUAD tissues and cells was assessed using the TCGA-LUAD database and quantitative reverse transcription polymerase chain reaction (qRT-PCR). The polarization of macrophages (derived from THP-1 cells) was examined through qRT-PCR, flow cytometry, and western blot to determine the influence of ANKRD22 on macrophage polarization. The effects of ANKRD22 knockdown on A549 cell proliferation and migration were measured using Cell Counting Kit-8 assay, colony formation, and Transwell assays. The impact of ANKRD22-induced macrophage M2 polarization on human umbilical vein endothelial cell (HUVEC) migration and angiogenesis was evaluated with Transwell and tube formation assays. Results: The expression of ANKRD22 was elevated in LUAD tissue and cellular samples, and its overexpression promoted M2 polarization in macrophages. Blocking ANKRD22-mediated M2 polarization inhibited the migration and tube formation capacity of HUVEC cells. Conclusions: Our findings showed that ANKRD22 mediates the malignant progression of LUAD by inducing M2 polarization of tumor-associated macrophages, thereby promoting angiogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.